BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chen L, Zhou Q, Liu J, Zhang W. CTNNB1 Alternation Is a Potential Biomarker for Immunotherapy Prognosis in Patients With Hepatocellular Carcinoma. Front Immunol 2021;12:759565. [PMID: 34777372 DOI: 10.3389/fimmu.2021.759565] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Peng X, Gong C, Zhang W, Zhou A. Advanced development of biomarkers for immunotherapy in hepatocellular carcinoma. Front Oncol 2022;12:1091088. [PMID: 36727075 DOI: 10.3389/fonc.2022.1091088] [Reference Citation Analysis]
2 Guven DC, Erul E, Sahin TK, Dizdar O, Yalcin S, Sahin IH. The benefit of immunotherapy in patients with hepatocellular carcinoma: a systematic review and meta-analysis. Future Oncology 2022. [DOI: 10.2217/fon-2022-0642] [Reference Citation Analysis]
3 Zhang X, Wen J, Zhang G, Fan W, Tan J, Liu H, Li J. Identification and Validation of Novel Immunogenic Cell Death- and DNA Damage Response-Related Molecular Patterns Correlated with Immune Status and Prognosis in Hepatocellular Carcinoma. Transl Oncol 2022;27:101600. [PMID: 36481605 DOI: 10.1016/j.tranon.2022.101600] [Reference Citation Analysis]
4 Testa U, Pelosi E, Castelli G. Clinical value of identifying genes that inhibit hepatocellular carcinomas. Expert Rev Mol Diagn 2022;22:1009-35. [PMID: 36459631 DOI: 10.1080/14737159.2022.2154658] [Reference Citation Analysis]
5 Meichen Liu, Wanpu Yan, Dongbo Chen, Jiancheng Luo, Liang Dai, Hongsong Chen, Ke-Neng Chen. IGFBP1hiWNT3Alo Subtype in Esophageal Cancer Predicts Response and Prolonged Survival with PD-(L)1 Inhibitor. Biology (Basel) 2022;11:1575. [PMID: 36358276 DOI: 10.3390/biology11111575] [Reference Citation Analysis]
6 Qu J, Sun F, Guan H, Hou Y, Qi H, Sun X, Xing L. The immune-related gene-based prognostic index predicts the prognosis and effect of immune checkpoint inhibitors in hepatocellular carcinoma.. [DOI: 10.21203/rs.3.rs-2092544/v1] [Reference Citation Analysis]
7 Li Z, Gao H, Zhang X, Liu Q, Chen G. Mutational and transcriptional alterations and clinicopathological factors predict the prognosis of stage I hepatocellular carcinoma: Prediction of stage I HCC prognosis. BMC Gastroenterol 2022;22. [DOI: 10.1186/s12876-022-02496-3] [Reference Citation Analysis]
8 Liu X, Zeng J, Li H, Li F, Jiang B, Zhao M, Liu Z, Li R, Ma T, Santhekadur PK. A Risk Model Based on Sorafenib-Response Target Genes Predicts the Prognosis of Patients with HCC. Journal of Oncology 2022;2022:1-18. [DOI: 10.1155/2022/7257738] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Zanotti S, Boot GF, Coto-llerena M, Gallon J, Hess GF, Soysal SD, Kollmar O, Ng CKY, Piscuoglio S. The Role of Chronic Liver Diseases in the Emergence and Recurrence of Hepatocellular Carcinoma: An Omics Perspective. Front Med 2022;9:888850. [DOI: 10.3389/fmed.2022.888850] [Reference Citation Analysis]
10 Nayak C, Singh SK. Integrated Transcriptome Profiling Identifies Prognostic Hub Genes as Therapeutic Targets of Glioblastoma: Evidenced by Bioinformatics Analysis. ACS Omega. [DOI: 10.1021/acsomega.2c01820] [Reference Citation Analysis]
11 Künstner A, Schwarting J, Witte HM, Bernard V, Stölting S, Kusch K, Nagarathinam K, von Bubnoff N, Murga Penas EM, Merz H, Busch H, Feller AC, Gebauer N. Integrative molecular profiling identifies two molecularly and clinically distinct subtypes of blastic plasmacytoid dendritic cell neoplasm.. [DOI: 10.1101/2022.05.26.22275640] [Reference Citation Analysis]